Incidence of hormone-dependent cancers such as those of the breast and prostate is increasing within the UK, with breast cancer constituting 15% of all diagnosed cancers, and 1 in 8 men receiving a prostate cancer diagnosis during their lifetime. Whilst both are curable when diagnosed at an early stage, late-stage diagnosis is common and patient survival dramatically reduced.

There is an urgent need both to identify new treatments for aggressive metastatic disease (and to identify who will respond best to such interventions), and to identify which early-stage tumours require upfront radical treatment to avoid the significant morbidities associated with over-treatment of indolent disease.

We aim to bring together a range of practitioners and researchers within hormone-dependent cancer, to share ideas, and develop essential strategies in this field.  

Why attend the Hormone Dependent Cancer conference?

• Stay up to date with the latest research and clinical techniques in hormone dependent cancers.
• Attend career development workshops and a ‘speed networking’ 
• Present your ideas and research in open discussion and lightening talks.
• Lectures from world-leading established researchers.

What topics will we be looking at?

• Genetics/ genomics of hormone-dependent cancers (HDCs)
• The role of the tumour microenvironment in driving HDCs
• Immuno-oncology approaches to the treatment of breast and prostate cancers
• Latest innovations in the development of novel therapeutics for HDCs
• New tools for cancer research; in particular novel patient-derived disease models.

Endorsing journal

Endocrine Oncology  is the official endorsing journal of the Hormone Dependent Cancer 2025 meeting. Endocrine Oncology is a Society for Endocrinology title publishing basic, translational and clinical research and reviews on the interplay between hormones and cancer, and related topics. It is a fully open-access journal, currently free to publish for a limited time only.